IL294582A - Methods for treating an enlarged spleen - Google Patents
Methods for treating an enlarged spleenInfo
- Publication number
- IL294582A IL294582A IL294582A IL29458222A IL294582A IL 294582 A IL294582 A IL 294582A IL 294582 A IL294582 A IL 294582A IL 29458222 A IL29458222 A IL 29458222A IL 294582 A IL294582 A IL 294582A
- Authority
- IL
- Israel
- Prior art keywords
- human subject
- btk inhibitor
- myeloid cells
- malignant
- inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Processing Of Solid Wastes (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062958632P | 2020-01-08 | 2020-01-08 | |
| PCT/US2021/012696 WO2021142257A1 (en) | 2020-01-08 | 2021-01-08 | Methods of treating splenomegaly |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL294582A true IL294582A (en) | 2022-09-01 |
Family
ID=76788747
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL294582A IL294582A (en) | 2020-01-08 | 2021-01-08 | Methods for treating an enlarged spleen |
Country Status (15)
| Country | Link |
|---|---|
| EP (2) | EP3980069A4 (https=) |
| JP (2) | JP7771064B2 (https=) |
| KR (1) | KR20220130151A (https=) |
| CN (1) | CN114423457A (https=) |
| AU (1) | AU2021205484A1 (https=) |
| BR (1) | BR112022013646A2 (https=) |
| CA (1) | CA3164063A1 (https=) |
| CO (1) | CO2022010592A2 (https=) |
| CR (1) | CR20220374A (https=) |
| IL (1) | IL294582A (https=) |
| JO (1) | JOP20220168A1 (https=) |
| MA (3) | MA63848B1 (https=) |
| MX (1) | MX2022008490A (https=) |
| TN (1) | TN2022000185A1 (https=) |
| WO (1) | WO2021142257A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3980069A4 (en) * | 2020-01-08 | 2022-08-17 | Telios Pharma, Inc. | METHODS OF TREATMENT OF SPLENOMEGALY |
| US20240024314A1 (en) | 2020-01-08 | 2024-01-25 | Telios Pharma, Inc. | Methods of Treating Splenomegaly |
| IL309238A (en) * | 2021-06-16 | 2024-02-01 | Telios Pharma Inc | Treatment of symptoms associated with myeloproliferative tumors |
| WO2023071973A1 (en) * | 2021-10-26 | 2023-05-04 | Shenzhen Targetrx, Inc. | Fused bicyclic compound for inhibiting activity of tyrosine kinase |
| CN119677518A (zh) * | 2022-08-25 | 2025-03-21 | 百济神州(苏州)生物科技有限公司 | 包含(s)-7-(1-丙烯酰基哌啶-4-基)-2-(4-苯氧基苯基)-4,5,6,7-四氢吡唑并[1,5-a]嘧啶-3-甲酰胺和草酸的固体形式、其组合物及其使用方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015057992A1 (en) * | 2013-10-16 | 2015-04-23 | Izumi Raquel | Btk inhibitors for hematopoietic mobilization |
| WO2015081127A2 (en) | 2013-11-26 | 2015-06-04 | Gilead Sciences, Inc. | Therapies for treating myeloproliferative disorders |
| MA40596B1 (fr) * | 2014-08-11 | 2021-12-31 | Acerta Pharma Bv | Combinaisons thérapeutiques d'un inhibiteur de btk et d'un inhibiteur de bcl-2 |
| WO2016054491A1 (en) * | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| CN112313214A (zh) * | 2018-06-19 | 2021-02-02 | 默克专利有限公司 | 1-(4-{[6-氨基-5-(4-苯氧基-苯基)-嘧啶-4-基氨基]-甲基}-4-氟代-哌啶-1-基)-丙烯酮及其盐形式的新晶体形式以及获得方法 |
| CN109942835A (zh) * | 2019-03-27 | 2019-06-28 | 广州楹鼎生物科技有限公司 | 一种催化分解木质纤维原料的方法 |
| TW202128156A (zh) * | 2019-11-14 | 2021-08-01 | 美商夸格智財控股有限公司 | 用於癌症治療之btk抑制劑及mdm2抑制劑之組合 |
| EP3980069A4 (en) * | 2020-01-08 | 2022-08-17 | Telios Pharma, Inc. | METHODS OF TREATMENT OF SPLENOMEGALY |
-
2021
- 2021-01-08 EP EP21738476.7A patent/EP3980069A4/en active Pending
- 2021-01-08 MA MA63848A patent/MA63848B1/fr unknown
- 2021-01-08 BR BR112022013646A patent/BR112022013646A2/pt unknown
- 2021-01-08 CR CR20220374A patent/CR20220374A/es unknown
- 2021-01-08 AU AU2021205484A patent/AU2021205484A1/en active Pending
- 2021-01-08 MX MX2022008490A patent/MX2022008490A/es unknown
- 2021-01-08 TN TNP/2022/000185A patent/TN2022000185A1/en unknown
- 2021-01-08 IL IL294582A patent/IL294582A/en unknown
- 2021-01-08 JP JP2022542216A patent/JP7771064B2/ja active Active
- 2021-01-08 KR KR1020227027305A patent/KR20220130151A/ko active Pending
- 2021-01-08 WO PCT/US2021/012696 patent/WO2021142257A1/en not_active Ceased
- 2021-01-08 CA CA3164063A patent/CA3164063A1/en active Pending
- 2021-01-08 EP EP22150344.4A patent/EP4000624A1/en active Pending
- 2021-01-08 MA MA57226A patent/MA57226B1/fr unknown
- 2021-01-08 MA MA69153A patent/MA69153A1/fr unknown
- 2021-01-08 CN CN202180004918.1A patent/CN114423457A/zh active Pending
-
2022
- 2022-07-07 JO JOP/2022/0168A patent/JOP20220168A1/ar unknown
- 2022-07-28 CO CONC2022/0010592A patent/CO2022010592A2/es unknown
-
2025
- 2025-11-05 JP JP2025186533A patent/JP2026027353A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4000624A1 (en) | 2022-05-25 |
| AU2021205484A1 (en) | 2022-08-18 |
| JP2026027353A (ja) | 2026-02-18 |
| MA57226B1 (fr) | 2023-06-28 |
| CR20220374A (es) | 2023-01-25 |
| MA57226A1 (fr) | 2023-02-28 |
| EP3980069A1 (en) | 2022-04-13 |
| JOP20220168A1 (ar) | 2023-01-30 |
| CO2022010592A2 (es) | 2022-10-31 |
| MX2022008490A (es) | 2022-10-13 |
| MA63848A1 (fr) | 2024-04-30 |
| JP2023509968A (ja) | 2023-03-10 |
| MA63848B1 (fr) | 2024-10-31 |
| TN2022000185A1 (en) | 2024-04-01 |
| MA69153A1 (fr) | 2025-07-31 |
| KR20220130151A (ko) | 2022-09-26 |
| CA3164063A1 (en) | 2021-07-15 |
| WO2021142257A1 (en) | 2021-07-15 |
| JP7771064B2 (ja) | 2025-11-17 |
| BR112022013646A2 (pt) | 2022-10-04 |
| EP3980069A4 (en) | 2022-08-17 |
| CN114423457A (zh) | 2022-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL294582A (en) | Methods for treating an enlarged spleen | |
| Brown et al. | Low-dose naltrexone for disease prevention and quality of life | |
| EP4358965A1 (en) | Erk1/2 and shp2 inhibitors combination therapy | |
| JPH02240021A (ja) | 抑うつ障害の治療用に適した制御放出製薬組成物 | |
| JP2021523220A5 (https=) | ||
| IL278345B2 (en) | Methods of treating cancer | |
| WO2007143146A2 (en) | Method of treating inflammatory diseases using tyroskine kinase inhibitors | |
| CN118059108B (zh) | 一种药物组合物及其在制备抗肿瘤药物中的应用 | |
| RU2323739C1 (ru) | Способ лечения больных туберкулезом легких | |
| US20240024314A1 (en) | Methods of Treating Splenomegaly | |
| JPWO2021142257A5 (https=) | ||
| US20240216333A1 (en) | Treatment of glioblastoma | |
| JP7186214B2 (ja) | 自己免疫性神経筋疾患を処置するためのクラドリビンの使用 | |
| Tuckman et al. | Clinical trial of an alpha adrenergic receptor stimulating drug (clonidine) for treatment of spasticity in spinal cord injured patients | |
| JPWO2019213074A5 (https=) | ||
| WO2023114225A1 (en) | Pharmaceutical combination comprising abemaciclib and a pi3k and/or a mtor inhibitor for the treatment of mantle cell lymphoma | |
| WO2022074599A1 (en) | Use of an erk inhibitor for the treatment of myelofibrosis | |
| WO2022074600A1 (en) | Use of an erk inhibitor for the treatment of myelofibrosis | |
| Hassin-Baer et al. | An open trial of amantadine and buspirone for cerebellar ataxia: a disappointment | |
| CN112533604A (zh) | 用于治疗癌症的组合疗法 | |
| US20240269120A1 (en) | Method for Treating an Autoimmune and Inflammatory Disease | |
| CN120202006A (zh) | 卡帕塞替尼和维奈托克的治疗组合 | |
| RU2344852C1 (ru) | Способ лечения больных гипертонической болезнью | |
| Zubieta et al. | Depression after cyproheptadine: MAO treatment. | |
| Chaplin | Janus kinase inhibitors for inflammatory bowel disease |